Ireland
--:--IST
Priya Life Science Regulatory
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 9 Nov 2026
1,195Technology appraisals published
90%Of 903 current decided appraisals recommend for at least some patients
78Published in 2026 so far
984Linked to a medicine page here

NICE has published 1,195 technology appraisals since 2000, and 1,068 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1195, published 30 Sep 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
  • Recommended: the NHS in England should fund it for the use it is licensed for.
  • Optimised: recommended, but for a narrower group of patients than the licence covers.
  • Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
  • Only in research: to be used only as part of a study.
  • Not recommended: NICE decided the NHS should not fund it for this use.
  • Terminated: the company did not send evidence, so NICE could not make a recommendation.

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Appraisals matching “Gemcitabine”

13 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer
NICE TA1138
DurvalumabRecommended2 Mar 2026Current
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA1113
GlofitamabOptimised3 Dec 2025Current
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
NICE TA966
PembrolizumabTerminated (no company submission)24 Apr 2024Current
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
NICE TA944
DurvalumabRecommended10 Jan 2024Current
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
NICE TA560
BevacizumabTerminated (no company submission)20 Feb 2019Current
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
NICE TA476
—Optimised6 Sep 2017Current
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
NICE TA440
—Not recommended26 Apr 2017Current
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA389
Paclitaxel, Pegylated liposomal doxorubicin, Gemcitabine, Trabectedin, TopotecanRecommended Not recommended27 Apr 2016Current
Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
NICE TA360
—Not recommended28 Oct 2015Current
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
NICE TA285
BevacizumabNot recommended22 May 2013Current
Gemcitabine for the treatment of metastatic breast cancer
NICE TA116
GemcitabineRecommended24 Jan 2007Current
Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer
NICE TA26
Docetaxel, Gemcitabine, Paclitaxel, VinorelbineRecommended26 Jun 2001Replaced
Guidance on the use of gemcitabine for the treatment of pancreatic cancer
NICE TA25
GemcitabineRecommended Not recommended8 May 2001Replaced

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.